The role of inflammatory markers in COVID-19 associated rhino-orbital-cerebral mucormycosis patients


  • Sunny Chopra Department of Biochemistry, Government Medical College, Patiala, Punjab, India
  • Maninder Kaur Department of Biochemistry, Government Medical College, Patiala, Punjab, India
  • Sanjeev Bhagat Department of E.N.T, Government Medical College, Patiala, Punjab, India
  • Vishav Yadav Department of E.N.T, Government Medical College, Patiala, Punjab, India



D-dimer, Procalcitonin , MCR , Ferritin, COVID-19


Background: India has experienced an unprecedented heave of mucormycosis (MCR) cases during second wave of COVID-19. Possible mechanisms may involve immune and inflammatory processes. The aim of the study is to estimate the role of inflammatory markers for triaging patients of COVID-19 associated rhino-orbital-cerebral mucormycosis (CAROCM) at tertiary care hospital in north India.

Methods: A retrospective observational study was conducted between September 2021 to December 2021, at Government medical college and hospital, Patiala (Pb), 83 CAROCM patients admitted in ENT department were evaluated for serum ferritin, D-dimer and PCT.

Results: The median age of the patients was 50 years. The number of male patients were 45 and female patients were 38. Based upon the medical history and associated comorbidities involved, 83 CAROCM patients were divided into three groups. 43 diabetic patients in group I, 33 patients with multiple risk factors in group II and 7 patients with no comorbidity in group III. The mean D-dimer levels were 702 ng/ml in group 1, 831ng/ml in group II and 399 ng/ml in group III, and ferritin levels were 522 ng/ml, 711 ng/ml and 426 ng/ml in group I, II and III respectively. Mean PCT levels in group I were 0.27 ng/ml, 1.32 ng/ml in group II and 0.42 ng/ml in group III.

Conclusions: Our study concluded that a significant association was observed between levels of inflammatory markers and susceptibility factors. Serum ferritin, D-dimer and procalcitonin, can be used for assessing the severity of infection and decreases the mortality and morbidity in CAROCM patients. 


Worldometer. Coronavirus cases: India. 2021. Available at: coronavirus/country/india/. Accessed on 15 July 2023.

Chander J, Kaur M, Bhalla M, Punia RS, Singla N, Bhola K, et al. Changing epidemiology of mucoralean fungi: chronic cutaneous infection caused by Mucor irregularis. Mycopathologia. 2015;180:181-6.

Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13:236-301.

Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-69.

Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(1):S23-34.

Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146.

Bawankar P, Lahane S, Pathak P, Gonde P, Singh A. Central retinal artery occlusion as the presenting manifestation of invasive rhino-orbital-cerebral mucormycosis. Taiwan J Ophthalmol. 2020;10(1):62-5.

Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021:69:244-52.

Sugar AM. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed. Philadelphia, PA, Elsevier. 2005;2979.

Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-53.

Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. In J Infect Dis. 2020;95:304-07.

Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021:69:244-52.

Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020;56(2):106051.

Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pr. 2011;94:311-21.

Federation, International Diabetes. Idf Diabetes Atlas. 2019. Available at: en/resources/. Accessed on 9 April 2023.

Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicenter observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26:944.e9-15.

About Mucormycosis, Mucormycosis, CDC. Available at: mucormycosis/def inition.html. Accessed on 05 May 2023.

Pal R, Banerjee M, Yadav U, Bhattacharjee S. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature. Diabetes Metab Syndr. 2020;14:1563-9.

Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect. Dis Clin N Am. 2016;30:143-63.

Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J, et al. A Prospective Multicenter Study on Mucormycosis in India: Epidemiology, Diagnosis, and Treatment. Med Mycol. 2019;57:395-402.

Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes. 1982;31:1109-14.

Waizel-Haiat S, Guerrero-Paz J, Sanchez-Hurtado L, Calleja-Alarcon S, RomeroGutierrez L. A case of fatal Rhino-Orbital Mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. 2021;13(2):e13163.

Maertens J, Demuynck H, Verbeken EK, Zachée P, Verhoef GE, Vandenberghe P, et al. Mucormycosis in allogeneic bone marrow transplant recipients: Report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24(3):307-12.

Sugar AM. Mucormycosis. Clin Infect Dis. 1992;14:126-29.

Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral Mucormycosis and COVID-19 Pneumonia. J Med Cases. 2021;12(3):85-9.

Selarka, L, Sharma, S, Saini, D. Mucormycosis and COVID-19: An epidemic within a pandemic in India. Mycoses. 2021;64:1253-60.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson J. COVID19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-34.

Vargas-Vargas M, Cortés-Rojo C. Ferritin levels and COVID-19. Rev Panam Salud Publica. 2020;44:72.

Asakura H, Haruhiko O. COVID-19 associated coagulopathy and disseminated intravascular coagulation. Int J Hematol. 2020;113(1):45-57.

Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782-92.

Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with COVID-19. J Thromb Haemostasis 2020;18:1324-9.

Torres Acosta MA, Singer BD. Pathogenesis of COVID-19-induced ARDS: implications for an ageing population. Eur Respir J. 2020;56(3):2002049.

Gautam S, Cohen AJ, Stahl Y, Valda Toro P, Young GM, Datta R, et al. Severe respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia. Thorax. 2020;75(11):974-81.

Banerjee M, Pal R, Bhadada SK. Intercepting the deadly trinity of mucormycosis, diabetes and COVID-19 in India. Postgrad Med J. 2021;98(e2):e108-9.




How to Cite

Chopra, S., Kaur, M., Bhagat, S., & Yadav, V. (2023). The role of inflammatory markers in COVID-19 associated rhino-orbital-cerebral mucormycosis patients. International Journal of Research in Medical Sciences, 11(11), 4107–4112.



Original Research Articles